Open the EF-01 platform page and you'll find stretch marks buried in the indications list between fine wrinkles and mild laxity. One line item. No explanation. This is the file behind that line — what the lesion is, why a water-targeting fractional laser ended up as the standard tool for it, and what you should tell a patient before the first session. It's technical background for buyers and operators, not medical advice. Protocol decisions belong to the clinician holding the handpiece.
What a stretch mark actually is
A stria is a dermal scar. Not a surface stain, not a pigment problem — a tear in the architecture of the dermis itself. Rapid mechanical stretch (pregnancy, growth spurts, fast weight change, corticosteroid exposure) outpaces the skin's ability to remodel, and the collagen and elastic fiber network in the dermis ruptures along lines of tension. A clinical review in the Journal of Cutaneous and Aesthetic Surgery describes the mature lesion as showing dermal atrophy with a disrupted, sparse elastic fiber network and reduced vascularity.
That single fact sets the engineering problem. The damage sits in the dermis, under an intact epidermis. Any device that hopes to change the lesion has to deliver energy through the surface and remodel collagen at depth. Creams that never reach the dermis don't have a mechanism. Superficial peels don't either. You need controlled dermal injury — which is exactly what a fractional laser is built to produce.
Our technical documentation on skin structure makes the same point from the other direction: dermal collagen is dominated by type I and type III fibers, and it's the ratio and organization of those fibers that decide whether skin looks like skin or like scar. Striae are a disorganization problem. Treatment is a re-organization job.
Red versus white: two different lesions
Age changes what you're treating. The distinction matters enough that most published work splits the two.
Striae rubrae
Fresh marks. Pink to violaceous, sometimes slightly raised, sometimes itchy. Histology shows active inflammation and dilated vessels — the lesion still has blood flow and a live repair process running. Two consequences follow. First, rubrae are the more responsive stage; the literature review cited above is blunt that early treatment does better. Second, part of what the patient sees is redness, and redness is a vascular signal, not a texture defect. A 1550 nm beam targets water, not hemoglobin, so it does nothing for the color directly. The erythema fades on its own over months as the lesion matures. If a patient's main complaint is the red itself, a vascular-targeting device is the honest answer — our vascular lesion notes cover that territory.
Striae albae
Mature marks. White, atrophic, finely wrinkled, often slightly depressed. The inflammation is gone, the vessels have regressed, melanocyte activity in the lesion is reduced — which is why albae stay pale even when surrounding skin tans. These are the marks most patients actually bring to a clinic, usually years after they formed. They respond, but slower and less completely than rubrae. The texture and depression improve with dermal remodeling. The pale color is the stubborn part, because repigmentation depends on melanocytes recolonizing the lesion, and no amount of collagen stimulation guarantees that.
Why non-ablative fractional took the job
Three device families have been thrown at striae: ablative fractional (CO2, Er:YAG), non-ablative fractional (1540/1550/1565 nm erbium glass), and everything else — vascular lasers, RF, microneedling, light devices. The non-ablative fractional group became the workhorse for a practical reason: the risk-to-benefit math on body skin.
Striae live on the abdomen, flanks, breasts, thighs, buttocks. Trunk and limb skin heals slower than facial skin — fewer pilosebaceous units means fewer reservoirs of regenerating cells. An ablative column that closes in days on a cheek can stay open much longer on an abdomen, and prolonged healing off the face raises the odds of post-inflammatory hyperpigmentation and, at the extreme, scarring. A non-ablative column sidesteps most of that. The 1550 nm wavelength is absorbed by tissue water, coagulating a narrow cone of dermis while the epidermis stays essentially closed. The untreated tissue between columns supplies the repair. That's the fractional photothermolysis concept Manstein and colleagues published in 2004, and striae are close to the ideal use case for it: dermal damage needing dermal remodeling, on body sites where you can't afford open wounds.
Does it work? The evidence says yes, with a ceiling. A long-term follow-up study of pregnancy-induced striae treated with a 1550 nm non-ablative fractional laser — five sessions, roughly monthly — measured striae that were visibly narrower and shorter after the course, with the improvement holding at extended follow-up. Reviews across the device class report the same shape of result: consistent partial improvement, essentially never complete clearance. Hold onto that phrase. It's the whole expectations conversation in four words.
Setting up for striae work
The full parameter architecture — spot sizes across lens cones, the 2 to 200 mJ energy range, density options from 36 to 576 spots per square centimetre, scan areas up to 3×3 cm — is on the EF-01 page and in the platform manual in our engineering archive. What's worth adding here is how striae shift the choices.
Coverage over intensity
Striae are long, linear, and spread over large areas. You're painting stripes across an abdomen, not spot-treating a scar on a cheek. The rectangular scan pattern earns its place here — align it along the stria and you treat the lesion without dosing healthy skin either side. The 3×3 cm area setting keeps session times sane on large fields. And the scanner's randomized firing order matters more than usual, because long overlapping passes on thin trunk skin are exactly where sequential heat stacking would hurt.
Conservative dosing, always
The protocol tables in our device documentation are built around facial work. Body sites don't inherit those numbers. Trunk skin is a different healing environment, and stretched atrophic skin inside a stria is thinner than the skin around it. Start low, test-patch on a discreet section of one stria, and review it before committing to a full field. Density is the lever to respect: published safety experience with 1550 nm devices ties pigment trouble to aggressive density and energy, not to the wavelength. On darker phototypes that caution doubles — the ceilings we walked through in Fitzpatrick and parameter ceilings apply to body work with no discount.
One contraindication that decides scheduling
Pregnancy is on the platform's contraindication list. Which is awkward, because pregnancy is when the most motivated patients appear. The practical consequence: striae gravidarum get treated postpartum, on the clinician's timing call — and since fresh rubrae respond best, that post-delivery window is worth not wasting. A clinic that explains this to a pregnant enquirer, books the consult for later, and treats early in the rubra stage will get better photos than one that waits for the marks to turn white.
The expectations file
This is where cases go wrong, so write it down and say it out loud at consult. Improvement, not erasure. A realistic course is several sessions — published striae protocols cluster around four to six, spaced about a month apart — and the visible change lags the treatment, because collagen remodeling runs for months after the last pass. The fair comparison photo is taken around three months post-course, under the same light, at the same angle. Width narrows, depression shallows, texture smooths. The white color of mature albae is the least movable feature, and anyone promising full disappearance of white striae is selling something the literature doesn't support.
One more boundary. Deep, wide, sharply atrophic striae behave like atrophic scars generally: at some depth of tissue loss, coagulation alone stops being enough. That's when the decision tree in our scar treatment notes comes into play, including when an ablative platform earns its downtime. Knowing where your device's job ends is part of running it well.
Frequently asked questions
How many sessions before the patient sees anything?
Usually not after one. Published striae courses run several sessions at roughly monthly intervals, and the dermal remodeling that changes the mark's appearance continues for months after the final session. Set the review-and-photograph point around three months post-course. Patients who expect week-one results will call it a failure at exactly the moment the biology is starting to work.
Do red stretch marks need a different machine?
Sometimes two machines share the case. The redness in striae rubrae is vascular, and 1550 nm light isn't absorbed by hemoglobin, so the fractional laser addresses texture and width while the color fades on its own schedule or gets targeted separately with a vascular device. The upside of treating at the red stage is that the lesion is still biologically active and responds better than mature white marks do.
Can I treat someone who is pregnant or just gave birth?
Pregnancy is listed as a contraindication in the platform's operating documentation, so treatment waits until after delivery, with the exact timing a clinical judgement call. It's worth booking that follow-up consult rather than losing the patient, because the early postpartum rubra stage is the most treatable window the marks will ever have.
Will treated stretch marks come back?
The remodeled collagen in a treated stria doesn't spontaneously revert — long-term follow-up data on 1550 nm treatment of pregnancy striae showed improvement holding well after the course ended. But treatment doesn't immunize skin. A later pregnancy or rapid weight change can create new striae in the same region, and patients should hear that distinction before they pay for a course.
Where do I find the full platform specification?
Complete parameters, acceptance checks and safety requirements are on the EF-01 product page . For a quotation at the source power that fits your case mix, contact us .
References
- Al-Himdani S, Ud-Din S, Gilmore S, Bayat A. Management of stretch marks (with a focus on striae rubrae). J Cutan Aesthet Surg / PubMed record
- Long-term results of the treatment of pregnancy-induced striae distensae using a 1550-nm non-ablative fractional laser. PubMed record
- Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR. Fractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg Med. 2004